What factors are contributing to the 30% increase in manufacturing defects for GSK's Trelegy Ellipta inhalers over the last two months?

Introduction

The recent 30% increase in manufacturing defects for GSK's Trelegy Ellipta inhalers over the last two months is a critical issue that demands immediate attention. As we analyze this product quality problem, I'll follow a systematic framework to identify, validate, and address the root cause while considering both immediate and long-term implications for GSK's respiratory product line.

I'll approach this issue by first clarifying key details, ruling out external factors, and then diving deep into the product, metrics, and potential internal causes. We'll generate data-driven hypotheses, conduct root cause analysis, and develop a comprehensive plan to resolve the issue and prevent future occurrences.

Step 1

Clarifying Questions (3 minutes)

• Looking at the timing, I'm thinking there might have been a recent change in the manufacturing process. Has there been any modification to the production line or materials in the last 3-4 months?

Why it matters: Recent changes often correlate with quality issues. Expected answer: Yes, there was a change in a supplier for a key component. Impact on approach: If confirmed, we'd focus on supplier quality control and integration.

• Considering the specificity of the 30% increase, I'm curious about our defect detection process. Has there been any change in our quality control procedures or equipment recently?

Why it matters: Changes in measurement can sometimes be mistaken for changes in the actual defect rate. Expected answer: No changes in QC processes. Impact on approach: If unchanged, we'd focus on the manufacturing process itself rather than measurement issues.

• Given the complexity of the Trelegy Ellipta inhaler, I'm wondering if the defects are concentrated in a particular component or step of the assembly. Do we have data on which specific parts or stages of production are most affected?

Why it matters: Pinpointing the location of defects can dramatically narrow our focus. Expected answer: Defects are primarily in the dose counter mechanism. Impact on approach: We'd concentrate on the dose counter assembly process and related components.

• Considering potential environmental factors, have there been any significant changes in the manufacturing environment, such as temperature, humidity, or air quality control systems?

Why it matters: Environmental factors can have subtle but significant impacts on precision manufacturing. Expected answer: No notable environmental changes reported. Impact on approach: If confirmed, we'd look more closely at material properties or human factors.